Page last updated: 2024-08-23

cabergoline and Pituitary ACTH Hypersecretion

cabergoline has been researched along with Pituitary ACTH Hypersecretion in 44 studies

Research

Studies (44)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	5 (11.36)	29.6817
2010's	27 (61.36)	24.3611
2020's	12 (27.27)	2.80

Authors

Authors	Studies
Colao, A; De Martino, MC; Pivonello, C; Pivonello, R; Simeoli, C	1
Gadelha, MR; Shimon, I; Wildemberg, LE	1
Costa, MCB; Czepielewski, MA; de Melo, RB; Mattos, ACV; Rodrigues, TDC; Viecceli, C	1
Cecenarro, LA; Fux-Otta, C; Murillo, NB; Ramacciotti, CF	2
Ciftci, S; Ersungur, EB; Gul, N; Kadioglu, P; Ozkaya, HM; Poyraz, BC; Sahin, S; Sarac, B; Sulu, C; Tanrikulu, S; Tanriover, E; Yener Ozturk, F	1
Bex, M; Biller, BMK; Boguszewski, CL; Chattopadhyay, A; Feelders, RA; Fleseriu, M; González-Devia, D; Kadioglu, P; Maamari, R; Patino, H; Pedroncelli, AM; Pivonello, R; Yavuz, DG	1
Biller, BMK; Tritos, NA	2
Lin, S; Wu, ZB; Zhang, A; Zhang, X	1
Bandgar, T; Goel, A; Goroshi, M; Gupta, T; Jalali, R; Krishnatry, R; Lila, A; Memon, SS; Patil, V; Ramteke-Jadhav, S; Sankhe, S; Sarathi, V; Shah, A; Shah, NS; Thakkar, K	1
Arvigo, M; Bruzzone, E; Dogan, F; Feelders, RA; Ferone, D; Gatto, F; Hofland, L; Lamberts, S; van der Pas, R; van Koetsveld, P	1
Giraldi, EA; Ioachimescu, AG	1
Ayala, A; Biller, BMK; Bonert, V; Broder, MS; Carmichael, JD; Cherepanov, D; Eagan, M; Geer, EB; Gordon, MB; Hannoush, Z; Katznelson, L; Lalazar, Y; Lee, J; Manuylova, E; Neary, MP; Pulaski-Liebert, KJ; Said, Q; Shafiq, I; Surampudi, V; Swerdloff, RS	1
Seow, CJ; Young, WF	1
Deepak, DS; Lee, KO; Sek, KS	1
Feelders, RA; Hofland, LJ; Lacroix, A; Newell-Price, J; Nieman, LK; Pivonello, R	1
Durgia, H; Kamalanathan, S; Kar, SS; Palui, R; Sahoo, J; Selvarajan, S	1
Reincke, M; Theodoropoulou, M	1
Albiger, N; Barbot, M; Ceccato, F; Denaro, L; Frigo, AC; Mantero, F; Scaroni, C; Zilio, M	1
Nieman, LK	1
Ehsanipoor, RM; Woo, I	1
Baltacıoğlu, F; Cebeci, AN; Dursun, F; Güven, A; Kırmızıbekmez, H	1
Gadelha, MR; Vieira Neto, L	1
Danser, AH; de Bruin, C; Feelders, RA; Hofland, LJ; Lamberts, SW; Netea-Maier, R; Pereira, AM; Sprij-Mooij, DM; van den Berg-Garrelds, IM; van den Meiracker, AH; van der Pas, R; van Esch, JH; van Schaik, RH; Zelissen, PM	1
Hamrahian, AH; Hoffman, AR; Yuen, KC	1
Galofré, JC; Pascual-Corrales, E; Salvador, J; Tomás Velázquez, A; Zubieta, JL	1
Burman, P; Edén-Engström, B; Ekman, B; Karlsson, FA; Schwarcz, E; Wahlberg, J	1
Ishikura, R; Koyama, H; Kurajoh, M; Moriwaki, Y; Namba, M; Okazaki, H; Shiraishi, J; Shirakawa, M; Shoji, T; Yamamoto, T	1
Ahmad, MS; Nakhleh, A; Pearl, IW; Reut, M; Saiegh, L; Shechner, C	1
Beckers, A; Bertherat, J; Briet, C; Caron, P; Castinetti, F; Cephise-Velayoudom, FL; Chabre, O; Chanson, P; Cortet, C; Delemer, B; Ferriere, A; Haissaguerre, M; Maiter, D; Nunes, ML; Raingeard, I; Reznik, Y; Rohmer, V; Tabarin, A; Vroonen, L	1
Cappabianca, P; Colao, A; De Leo, M; De Martino, MC; Faggiano, A; Hofland, LJ; Lamberts, SW; Lombardi, G; Pivonello, R	1
Agra, R; Albuquerque, JL; Arahata, CM; Arruda, MJ; Azevedo, MF; Canadas, V; Montenegro, L; Moura E Silva, L; Naves, LA; Pontes, L; Vilar, L	1
de Bruin, C; de Herder, WW; de Jong, FH; Feelders, RA; Hermus, AR; Hofland, LJ; Lamberts, SW; Netea-Maier, RT; Pereira, AM; Romijn, JA; van der Lely, AJ; van Heerebeek, R; Zelissen, PM	1
Beauregard, H; Bruno, OD; Danilowicz, K; Godbout, A; Lacroix, A; Manavela, M	1
Bruno, OD; Danilowicz, K; Manavela, MP	1
de Bruin, C; de Herder, WW; de Jong, FH; de Maat, MP; Feelders, RA; Hermus, AR; Hofland, LJ; Lamberts, SW; Leebeek, FW; Netea-Maier, RT; Pereira, AM; Rijken, DC; Romijn, JA; van der Lely, AJ; van der Pas, R; Zelissen, PM	1
Barahona Constanzo, MJ; del Pozo Picó, C	1
de Bruin, C; de Herder, WW; de Jong, FH; Feelders, RA; Hermus, AR; Hofland, LJ; Lamberts, SW; Netea-Maier, RT; Pereira, AM; Romijn, JA; van der Lely, AJ; van der Pas, R; Webb, SM; Zelissen, PM	1
Bianchi, A; De Marinis, L; Doglietto, F; Giampietro, A; Iacovazzo, D; Lauriola, L; Lucci-Cordisco, E; Lugli, F; Milardi, D	1
Date, I; Hashimoto, K; Inagaki, K; Makino, H; Miyoshi, T; Ogura, T; Otsuka, F; Suzuki, J; Takeda, M	1
Dubois-Ginouves, S; Illouz, F; Laboureau, S; Rodien, P; Rohmer, V	1
Cabrera Blatter, MF; Castillo, VA; García, JD; Gómez, NV; Lalia, JC	1
Alexandraki, KI; Grossman, AB	1

Reviews

15 review(s) available for cabergoline and Pituitary ACTH Hypersecretion

Article	Year
The dopaminergic control of Cushing's syndrome. Journal of endocrinological investigation, 2022, Volume: 45, Issue:7 Topics: Adrenal Gland Neoplasms; Cabergoline; Cushing Syndrome; Humans; Hydrocortisone; Pituitary ACTH Hypersecretion; Pituitary Diseases; Pituitary Neoplasms	2022
Pituitary acting drugs: cabergoline and pasireotide. Pituitary, 2022, Volume: 25, Issue:5 Topics: Cabergoline; Humans; Pituitary ACTH Hypersecretion; Pituitary Gland; Somatostatin	2022
Medical Management of Cushing Disease. Neurosurgery clinics of North America, 2019, Volume: 30, Issue:4 Topics: Cabergoline; Etomidate; Humans; Ketoconazole; Metyrapone; Mitotane; Pituitary ACTH Hypersecretion; Somatostatin; Temozolomide; Treatment Outcome	2019
Treatment of Pituitary and Other Tumours with Cabergoline: New Mechanisms and Potential Broader Applications. Neuroendocrinology, 2020, Volume: 110, Issue:6 Topics: Antineoplastic Agents; Cabergoline; Dopamine Agonists; Humans; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; Prolactinoma	2020
Advances in the Medical Treatment of Cushing Disease. Endocrinology and metabolism clinics of North America, 2020, Volume: 49, Issue:3 Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Cabergoline; Endocrinology; Humans; Mifepristone; Mitotane; Pituitary ACTH Hypersecretion; Somatostatin; Treatment Outcome	2020
The Role of Dopamine Agonists in Pituitary Adenomas. Endocrinology and metabolism clinics of North America, 2020, Volume: 49, Issue:3 Topics: Acromegaly; Adenoma; Cabergoline; Dopamine Agonists; Human Growth Hormone; Humans; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; Prolactinoma; Treatment Outcome	2020
Advances in the medical treatment of Cushing's syndrome. The lancet. Diabetes & endocrinology, 2019, Volume: 7, Issue:4 Topics: ACTH Syndrome, Ectopic; ACTH-Secreting Pituitary Adenoma; Adenoma; Adrenal Gland Neoplasms; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cabergoline; Cushing Syndrome; Dopamine Agonists; ErbB Receptors; Gefitinib; Hormones; Humans; Imidazoles; Isoquinolines; Molecular Targeted Therapy; Pituitary ACTH Hypersecretion; Pyrazoles; Pyridines; Receptors, Glucocorticoid; Roscovitine; Somatostatin; Temozolomide; Tretinoin	2019
Effect of cabergoline monotherapy in Cushing's disease: an individual participant data meta-analysis. Journal of endocrinological investigation, 2018, Volume: 41, Issue:12 Topics: Cabergoline; Dopamine Agonists; Humans; Pituitary ACTH Hypersecretion; Treatment Outcome	2018
Tumor-Directed Therapeutic Targets in Cushing Disease. The Journal of clinical endocrinology and metabolism, 2019, 03-01, Volume: 104, Issue:3 Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Antineoplastic Agents; Cabergoline; Clinical Trials as Topic; Corticotrophs; Humans; Pituitary ACTH Hypersecretion; Roscovitine; Silybin; Somatostatin; Treatment Outcome; Tretinoin	2019
Update in the medical therapy of Cushing's disease. Current opinion in endocrinology, diabetes, and obesity, 2013, Volume: 20, Issue:4 Topics: Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Humans; Hydrocortisone; Pituitary ACTH Hypersecretion; Somatostatin	2013
Efficacy of medical treatment in Cushing's disease: a systematic review. Clinical endocrinology, 2014, Volume: 80, Issue:1 Topics: Cabergoline; Ergolines; Female; Humans; Ketoconazole; Male; Metyrapone; Mitotane; Pituitary ACTH Hypersecretion; Somatostatin	2014
AACE/ACE Disease State Clinical Review: Medical Management of Cushing Disease. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2014, Volume: 20, Issue:7 Topics: Adrenocorticotropic Hormone; Cabergoline; Drug Therapy, Combination; Ergolines; Humans; Ketoconazole; Mifepristone; Pituitary ACTH Hypersecretion; Somatostatin	2014
New prospects for drug treatment in Cushing disease. Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2012, Volume: 59, Issue:10 Topics: Adenoma; Adrenocorticotropic Hormone; Animals; Cabergoline; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Drug Evaluation, Preclinical; Ergolines; Etomidate; Humans; Hydrocortisone; Imidazoles; Ketoconazole; Metyrapone; Mice; Mifepristone; Mitotane; Multicenter Studies as Topic; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; PPAR gamma; Pyridines; Rats; Somatostatin; Therapies, Investigational; Tretinoin	2012
Double pituitary adenomas. Endocrine, 2013, Volume: 43, Issue:2 Topics: Adenoma; Antineoplastic Agents; Cabergoline; Combined Modality Therapy; Comorbidity; Ergolines; Humans; Male; Middle Aged; Neoplasms, Multiple Primary; Neurosurgical Procedures; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; Treatment Outcome	2013
Pituitary-targeted medical therapy of Cushing's disease. Expert opinion on investigational drugs, 2008, Volume: 17, Issue:5 Topics: Adrenocorticotropic Hormone; Animals; Cabergoline; Dopamine Agonists; Ergolines; Humans; Neurotransmitter Agents; Oligopeptides; Pituitary ACTH Hypersecretion; Pituitary Gland; Somatostatin	2008

Trials

5 trial(s) available for cabergoline and Pituitary ACTH Hypersecretion

Article	Year
Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing's disease. Frontiers in endocrinology, 2023, Volume: 14 Topics: Cabergoline; Cushing Syndrome; Humans; Hydrocortisone; Pituitary ACTH Hypersecretion; Treatment Outcome	2023
Combination therapy for Cushing's disease: effectiveness of two schedules of treatment: should we start with cabergoline or ketoconazole? Pituitary, 2014, Volume: 17, Issue:2 Topics: Adult; Aged; Biomarkers; Cabergoline; Circadian Rhythm; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Ergolines; Female; Humans; Hydrocortisone; Ketoconazole; Male; Middle Aged; Pituitary ACTH Hypersecretion; Prospective Studies; Saliva; Treatment Outcome	2014
Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. The New England journal of medicine, 2010, May-13, Volume: 362, Issue:19 Topics: Adult; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Humans; Hydrocortisone; Ketoconazole; Male; Middle Aged; Pituitary ACTH Hypersecretion; Prospective Studies; Receptors, Dopamine D2; Receptors, Somatostatin; Somatostatin	2010
The hypercoagulable state in Cushing's disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy. The Journal of clinical endocrinology and metabolism, 2012, Volume: 97, Issue:4 Topics: Adult; Aged; Blood Coagulation; Blood Coagulation Factors; Cabergoline; Dopamine Agonists; Drug Monitoring; Drug Resistance; Drug Therapy, Combination; Ergolines; Fibrinolysis; Humans; Hydrocortisone; Ketoconazole; Male; Middle Aged; Pituitary ACTH Hypersecretion; Pituitary Hormones, Anterior; Remission Induction; Somatostatin; Thrombophilia; Young Adult	2012
Cushing's disease in dogs: cabergoline treatment. Research in veterinary science, 2008, Volume: 85, Issue:1 Topics: Adrenocorticotropic Hormone; alpha-MSH; Animals; Cabergoline; Dog Diseases; Dogs; Dopamine Agonists; Ergolines; Female; Ketoconazole; Male; Pituitary ACTH Hypersecretion; Time Factors	2008

Other Studies

24 other study(ies) available for cabergoline and Pituitary ACTH Hypersecretion

Article	Year
Evaluation of ketoconazole as a treatment for Cushing's disease in a retrospective cohort. Frontiers in endocrinology, 2022, Volume: 13 Topics: Cabergoline; Cushing Syndrome; Humans; Hydrocortisone; Hypokalemia; Ketoconazole; Pituitary ACTH Hypersecretion; Retrospective Studies	2022
Cushing's disease in pregnancy and treatment with cabergoline: obstetric and neonatal results Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina), 2023, 03-31, Volume: 80, Issue:1 Topics: Cabergoline; Colectomy; Female; Humans; Pituitary ACTH Hypersecretion; Pregnancy; Retrospective Studies; Tretinoin	2023
Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina), 2023, Mar-31, Volume: 80, Issue:1 Topics: Cabergoline; Colectomy; Female; Humans; Pituitary ACTH Hypersecretion; Pregnancy; Retrospective Studies; Tretinoin	2023
Risk of impulse control disorders in patients with Cushing's disease: do not blame cabergoline but do not give up caution. Pituitary, 2023, Volume: 26, Issue:4 Topics: Cabergoline; Cross-Sectional Studies; Depressive Disorder, Major; Disruptive, Impulse Control, and Conduct Disorders; Humans; Pituitary ACTH Hypersecretion; Prospective Studies	2023
Cabergoline may act as a radioprotective agent in Cushing's disease. Clinical endocrinology, 2020, Volume: 92, Issue:1 Topics: Adolescent; Adult; Cabergoline; Child; Female; Follow-Up Studies; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Pituitary ACTH Hypersecretion; Radiation-Protective Agents; Recurrence; Remission Induction; Retrospective Studies; Young Adult	2020
β-arrestin expression in corticotroph tumor cells is modulated by glucocorticoids. The Journal of endocrinology, 2020, Volume: 245, Issue:1 Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adult; Aged; Animals; Anti-Inflammatory Agents; beta-Arrestin 1; beta-Arrestin 2; Cabergoline; Cell Line, Tumor; Dexamethasone; Drug Therapy, Combination; Female; Gene Expression Regulation, Neoplastic; Glucocorticoids; Humans; Ketoconazole; Male; Mice; Middle Aged; Pituitary ACTH Hypersecretion; Pituitary Gland; Pituitary Neoplasms	2020
BIOCHEMICAL CONTROL DURING LONG-TERM FOLLOW-UP OF 230 ADULT PATIENTS WITH CUSHING DISEASE: A MULTICENTER RETROSPECTIVE STUDY. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2017, Volume: 23, Issue:8 Topics: 14-alpha Demethylase Inhibitors; ACTH-Secreting Pituitary Adenoma; Adenoma; Adolescent; Adrenalectomy; Adult; Aged; Antineoplastic Agents; Cabergoline; Comorbidity; Enzyme Inhibitors; Ergolines; Female; Follow-Up Studies; Hirsutism; Hormone Antagonists; Hormones; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Ketoconazole; Male; Metyrapone; Middle Aged; Mifepristone; Muscle Weakness; Muscular Atrophy; Neurosurgical Procedures; Obesity, Abdominal; Pituitary ACTH Hypersecretion; Pituitary Irradiation; Polycystic Ovary Syndrome; Retrospective Studies; Rosiglitazone; Somatostatin; Striae Distensae; Thiazolidinediones; Treatment Outcome; Tumor Burden; Young Adult	2017
An Overlooked Cause of Hypokalemia. The American journal of medicine, 2017, Volume: 130, Issue:10 Topics: 14-alpha Demethylase Inhibitors; Adenoma; Cabergoline; Cushing Syndrome; Dopamine Agonists; Ergolines; Female; Humans; Hypokalemia; Ketoconazole; Middle Aged; Pituitary ACTH Hypersecretion; Pituitary Neoplasms	2017
Use of cabergoline for the management of persistent Cushing's disease in pregnancy. BMJ case reports, 2017, Jul-14, Volume: 2017 Topics: Adult; Antineoplastic Agents; Cabergoline; Diagnosis, Differential; Ergolines; Female; Humans; Pituitary ACTH Hypersecretion; Pregnancy; Pregnancy Complications; Prenatal Diagnosis; Recurrence; Remission Induction	2017
Cabergoline therapy for Cushing disease throughout pregnancy. Obstetrics and gynecology, 2013, Volume: 122, Issue:2 Pt 2 Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Infant, Newborn; Live Birth; Pituitary ACTH Hypersecretion; Pregnancy; Pregnancy Complications	2013
Remission with cabergoline in adolescent boys with Cushing's disease. Journal of clinical research in pediatric endocrinology, 2013, Sep-10, Volume: 5, Issue:3 Topics: Adolescent; Cabergoline; Dopamine Agonists; Ergolines; Humans; Hypertension; Male; Petrosal Sinus Sampling; Pituitary ACTH Hypersecretion; Remission Induction	2013
Cushing's disease and hypertension: in vivo and in vitro study of the role of the renin-angiotensin-aldosterone system and effects of medical therapy. European journal of endocrinology, 2014, Volume: 170, Issue:2 Topics: Adult; Aged; Aldosterone; Angiotensinogen; Animals; Cabergoline; Ergolines; Female; Humans; Hypertension; Iliac Artery; In Vitro Techniques; Male; Middle Aged; Pituitary ACTH Hypersecretion; Rats; Renin; Renin-Angiotensin System; Somatostatin; Vasoconstriction	2014
Cabergoline for Cushing's disease: A case report. Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2015, Volume: 62, Issue:10 Topics: Adrenocorticotropic Hormone; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hydrocortisone; Magnetic Resonance Imaging; Middle Aged; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; Remission Induction; Tumor Burden	2015
Limited value of cabergoline in Cushing's disease: a prospective study of a 6-week treatment in 20 patients. European journal of endocrinology, 2016, Volume: 174, Issue:1 Topics: Adrenocorticotropic Hormone; Adult; Aged; Cabergoline; Circadian Rhythm; Dopamine Agonists; Ergolines; Female; Humans; Hydrocortisone; Male; Middle Aged; Pituitary ACTH Hypersecretion; Prospective Studies; Saliva	2016
Concomitant Cushing's Disease and Marked Hyperprolactinemia: Response to a Dopamine Receptor Agonist. Internal medicine (Tokyo, Japan), 2016, Volume: 55, Issue:8 Topics: Adrenocorticotropic Hormone; Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hydrocortisone; Hyperprolactinemia; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; Prolactin; Prolactinoma	2016
Cabergoline treatment for recurrent Cushing's disease during pregnancy. Hormones (Athens, Greece), 2016, Volume: 15, Issue:3 Topics: Adult; Antineoplastic Agents; Biomarkers; Cabergoline; Ergolines; Female; Humans; Hydrocortisone; Live Birth; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Neoplasm, Residual; Pituitary ACTH Hypersecretion; Pregnancy; Pregnancy Complications; Remission Induction; Treatment Outcome	2016
Cabergoline for Cushing's disease: a large retrospective multicenter study. European journal of endocrinology, 2017, Volume: 176, Issue:3 Topics: Adolescent; Adult; Aged; Cabergoline; Child; Ergolines; Female; Humans; Hydrocortisone; Male; Middle Aged; Pituitary ACTH Hypersecretion; Remission Induction; Retrospective Studies; Treatment Outcome; Young Adult	2017
The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. The Journal of clinical endocrinology and metabolism, 2009, Volume: 94, Issue:1 Topics: Adrenocorticotropic Hormone; Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hydrocortisone; Insulin Resistance; Male; Middle Aged; Pituitary ACTH Hypersecretion	2009
Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease. Pituitary, 2010, Volume: 13, Issue:2 Topics: Adult; Cabergoline; Drug Therapy, Combination; Ergolines; Female; Humans; Hydrocortisone; Ketoconazole; Male; Middle Aged; Pituitary ACTH Hypersecretion; Prospective Studies; Treatment Outcome	2010
Cabergoline monotherapy in the long-term treatment of Cushing's disease. European journal of endocrinology, 2010, Volume: 163, Issue:5 Topics: Adult; Aged; Cabergoline; Cohort Studies; Ergolines; Female; Follow-Up Studies; Humans; Hydrocortisone; Male; Middle Aged; Pituitary ACTH Hypersecretion; Recurrence; Retrospective Studies; Time Factors; Young Adult	2010
Macrocorticotropinoma shrinkage and control of hypercortisolism under long-term cabergoline therapy: case report. Pituitary, 2012, Volume: 15 Suppl 1 Topics: Adult; Cabergoline; Cushing Syndrome; Ergolines; Female; Humans; Magnetic Resonance Imaging; Pituitary ACTH Hypersecretion	2012
Cortisol diurnal rhythm and quality of life after successful medical treatment of Cushing's disease. Pituitary, 2013, Volume: 16, Issue:4 Topics: Adult; Aged; Cabergoline; Circadian Rhythm; Dopamine Agonists; Ergolines; Female; Humans; Hydrocortisone; Ketoconazole; Male; Middle Aged; Pituitary ACTH Hypersecretion; Quality of Life; Somatostatin; Surveys and Questionnaires; Young Adult	2013
Effect of cabergoline treatment on Cushing's disease caused by aberrant adrenocorticotropin-secreting macroadenoma. Journal of endocrinological investigation, 2004, Volume: 27, Issue:11 Topics: Adenoma; Adrenocorticotropic Hormone; Cabergoline; Dopamine Agonists; Ergolines; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; Receptors, Dopamine D2; Treatment Outcome	2004
[Use of cabergoline in persisting Cushing's disease]. Annales d'endocrinologie, 2006, Volume: 67, Issue:4 Topics: Adrenocortical Hyperfunction; Adult; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hydrocortisone; Magnetic Resonance Imaging; Middle Aged; Pituitary ACTH Hypersecretion	2006